Display options
Cite
Deodato F, Cilla S, Macchia G, et al. Extracranial radiosurgery with volumetric modulated arc therapy: Feasibility evaluation of a phase I trial. Oncol Lett. 2013;5(6):1889-1896doi: 10.3892/ol.2013.1276.
Deodato, F., Cilla, S., Macchia, G., Caravatta, L., Mignogna, S., Massaccesi, M., Picardi, V., Digesu, C., Sallustio, G., Bonomo, P., Piermattei, A., Ferrandina, G., Scambia, G., Valentini, V., Cellini, N., & Morganti, A. G. (2013). Extracranial radiosurgery with volumetric modulated arc therapy: Feasibility evaluation of a phase I trial. Oncology letters, 5(6), 1889-1896. https://doi.org/10.3892/ol.2013.1276
Deodato, Francesco, et al. "Extracranial radiosurgery with volumetric modulated arc therapy: Feasibility evaluation of a phase I trial." Oncology letters vol. 5,6 (2013): 1889-1896. doi: https://doi.org/10.3892/ol.2013.1276
Deodato F, Cilla S, Macchia G, Caravatta L, Mignogna S, Massaccesi M, Picardi V, Digesu C, Sallustio G, Bonomo P, Piermattei A, Ferrandina G, Scambia G, Valentini V, Cellini N, Morganti AG. Extracranial radiosurgery with volumetric modulated arc therapy: Feasibility evaluation of a phase I trial. Oncol Lett. 2013 Jun;5(6):1889-1896. doi: 10.3892/ol.2013.1276. Epub 2013 Mar 29. PMID: 23833662; PMCID: PMC3700848.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2013 Jun;5(6):1889-1896. doi: 10.3892/ol.2013.1276. Epub 2013 Mar 29.

Extracranial radiosurgery with volumetric modulated arc therapy: Feasibility evaluation of a phase I trial.

Oncology letters

Francesco Deodato, Savino Cilla, Gabriella Macchia, Luciana Caravatta, Samantha Mignogna, Mariangela Massaccesi, Vincenzo Picardi, Cinzia Digesu, Giuseppina Sallustio, Pierluigi Bonomo, Angelo Piermattei, Gabriella Ferrandina, Giovanni Scambia, Vincenzo Valentini, Numa Cellini, Alessio G Morganti

Affiliations

  1. Units of Radiotherapy, Fondazione di Ricerca e Cura "Giovanni Paolo II", Università Cattolica del S. Cuore;

PMID: 23833662 PMCID: PMC3700848 DOI: 10.3892/ol.2013.1276

Abstract

The aim of this study was to report early clinical experience in stereotactic body radiosurgery (SBRS) delivered using volumetric intensity modulated arc therapy (VMAT) in patients with primary or metastatic tumors in various extra-cranial body sites. Each enrolled subject was included in a different phase I study arm, depending on the tumor site and the disease stage (lung, liver, bone, metastatic), and sequentially assigned to a particular dose level. Technical feasibility and dosimetric results were investigated. The acute toxicity, tumor response and early local control were also studied. In total, 25 lesions in 20 consecutive patients (male/female, 11/9; median age, 67 years; age range, 47-86 years) were treated. Of these 25 lesions, 4 were primary or metastatic lung tumors, 6 were liver metastases, 8 were bone metastases and 7 were nodal metastases. The dose-volume constraints for organs at risk (OARs) were observed in 19 patients using a single-arc technique. Only in one patient were two arcs required. The treatment was performed without interruption or any other technical issues. The prescribed dose ranged from 12-26 Gy to the planning target volume (PTV). Delivery time ranged from 4 min to 9 min and 13 sec (median, 6 min and 6 sec). No incidence of grade 2-4 acute toxicity was recorded. The overall response rate was 48% (95% confidence interval (CI), 24.2-70.2) based on computed tomography (CT)/magnetic resonance imaging (MRI) and 89% (95% CI, 58.6-98.7) based on the positron emission tomography (PET) scan. SBRS delivered by means of VMAT allowed the required target coverage to be achieved while remaining within the normal tissue dose-volume constraints in the 20 consecutive patients. VMAT-SBRS resulted in adequate technical feasibility; the maximum tolerable dose has not yet been reached in any study arm.

Keywords: extracranial radiosurgery; feasibility; phase I; stereotactic body radiosurgery; volumetric intensity modulated arc therapy; volumetric modulated arc therapy

References

  1. Acta Oncol. 1995;34(6):861-70 - PubMed
  2. Eur J Cancer. 1999 Dec;35(13):1773-82 - PubMed
  3. Radiother Oncol. 2008 Dec;89(3):320-9 - PubMed
  4. Semin Radiat Oncol. 2008 Oct;18(4):215-22 - PubMed
  5. Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1041-6 - PubMed
  6. Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1278-84 - PubMed
  7. Acta Oncol. 2006;45(7):838-47 - PubMed
  8. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):608-16 - PubMed
  9. Radiother Oncol. 2010 Dec;97(3):431-6 - PubMed
  10. Oncol Rep. 2009 Aug;22(2):415-9 - PubMed
  11. Acta Oncol. 2011 May;50(4):528-38 - PubMed
  12. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1026-32 - PubMed
  13. Radiother Oncol. 2010 May;95(2):153-7 - PubMed
  14. Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1457-66 - PubMed
  15. Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):506-13 - PubMed
  16. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3 - PubMed
  17. Int J Clin Oncol. 2007 Feb;12(1):3-7 - PubMed
  18. Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):444-51 - PubMed
  19. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):974-8 - PubMed
  20. J Clin Oncol. 2001 Jan 1;19(1):164-70 - PubMed
  21. Technol Cancer Res Treat. 2010 Oct;9(5):499-507 - PubMed
  22. Acta Oncol. 1994;33(6):677-83 - PubMed
  23. Radiother Oncol. 2010 Feb;94(2):224-8 - PubMed
  24. Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:3401-4 - PubMed
  25. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 - PubMed
  26. Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):449-57 - PubMed
  27. Semin Radiat Oncol. 2006 Apr;16(2):77-84 - PubMed
  28. Cancer Nurs. 1988 Oct;11(5):303-8 - PubMed
  29. Radiother Oncol. 2010 Dec;97(3):437-42 - PubMed
  30. Neurosurgery. 2004 Jul;55(1):89-98; discussion 98-9 - PubMed
  31. Radiat Oncol. 2009 Jan 12;4:1 - PubMed
  32. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1560-7 - PubMed
  33. Strahlenther Onkol. 2011 Apr;187(4):238-44 - PubMed

Publication Types